SSR182289 is a selective, potent, and orally active thrombin inhibitor; it exhibits anticoagulant activity in vitro, inhibits tissue factor-induced thrombin generation in human plasma, and inhibits thrombin-induced human platelet aggregation without affecting aggregation induced by other platelet agonists.